Company Page

Life Biosciences is a clinical-stage biotechnology company based in Boston, Massachusetts, pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging. Co-founded by Harvard genetics professor David Sinclair, the company develops a proprietary partial epigenetic reprogramming platform that uses three Yamanaka factors to restore youthful gene expression in aged cells. In January 2026, Life Biosciences achieved a landmark milestone by receiving FDA approval for the first-ever human clinical trial of a partial epigenetic reprogramming therapy, targeting optic neuropathies such as glaucoma and NAION.

Company Founded in 2017

Healthtech & Biotech